Inhibikase Therapeutics (IKT) EBIAT (2020 - 2024)
Historic EBIAT for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.1 million.
- Inhibikase Therapeutics' EBIAT fell 19039.62% to -$12.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$27.5 million, marking a year-over-year decrease of 4462.17%. This contributed to the annual value of -$27.5 million for FY2024, which is 4462.17% down from last year.
- As of Q4 2024, Inhibikase Therapeutics' EBIAT stood at -$12.1 million, which was down 19039.62% from -$5.8 million recorded in Q3 2024.
- Inhibikase Therapeutics' 5-year EBIAT high stood at -$421869.0 for Q2 2020, and its period low was -$12.1 million during Q4 2024.
- Its 5-year average for EBIAT is -$4.1 million, with a median of -$4.5 million in 2022.
- Per our database at Business Quant, Inhibikase Therapeutics' EBIAT tumbled by 56674.67% in 2021 and then skyrocketed by 1512.54% in 2022.
- Inhibikase Therapeutics' EBIAT (Quarter) stood at -$1.2 million in 2020, then plummeted by 317.36% to -$5.0 million in 2021, then rose by 15.13% to -$4.3 million in 2022, then grew by 2.36% to -$4.2 million in 2023, then plummeted by 190.4% to -$12.1 million in 2024.
- Its EBIAT was -$12.1 million in Q4 2024, compared to -$5.8 million in Q3 2024 and -$5.0 million in Q2 2024.